Young people participated in the battle with the historical prevention test of Alzheimer’s disease

In order to move towards Alzheimer’s disease unprecedented, researchers are now recruiting participants under 18 years old for pioneering clinical trials, which aims to stop the disease before they can take root. This international study led by the University of Washington, the University of St. Louis, is the first time that scientists have tried to intervene for 25 years. This is the first time that scientists have tried to prevent Alzheimer’s disease.

The focus of the primary prevention test is that the individual of rare genetic mutations families. These individuals can actually ensure the development of Alzheimer’s disease, which is usually in their 30s, 40s, or in the 1950s. Despite the test for this specific group, researchers believe that these findings can completely change all forms of prevention strategies in Alzheimer’s disease.

Compete with time

“Over the past few years, we have made great progress in treating Alzheimer’s disease,” said Dr. Eric McDade, a professor and chief researcher at neurological professors and trials. “Show two starch -like protein targeting drugs that can slowly disease. Now it has been approved by the Food and Drug Administration as a mild cognitive impairment or mild dementia patients caused by Alzheimer’s disease. “” “

The study will test an antibody Remtertug developed by Eli Lilly and Company to remove or prevent the accumulation of amyloid protein β plaques in the brain. This is a key protein related to the development of Alzheimer’s disease. This accumulation is about 20 years before the memory problem has surfaced, providing a key window for intervention.

Personal battle

For the 24 -year -old Hannah Richardson, participating in the test has deep personal significance. She shared: “My grandfather died from Alzheimer’s disease, and all his mother and one of his brothers also died.” “My mother and uncle have participated in Dai since I was 10 years old. Dian’s trial. My mother is always very open to her diagnosis and how it inspires her advocacy of Alzheimer’s disease, I always know that I want to follow her. “

Innovation of treatment

The test introduces a treatment method that is more suitable for patients. Unlike Alzheimer’s disease approved by FDA, which needs frequent intravenous infusions, you can regenerate through the skin every three months through the skin. The study will recruit about 240 participants, two years of treatment, and expected results within four to five years.

Global efforts

This ambitious project has received considerable financial support, and has made more than $ 130 million investment from various sources. These include US $ 98.3 million from the National Institute of Aging, $ 14 million from the Alzheimer’s Association and the GHR Foundation, and the strong support of private donors and industry partners.

Dr. Maria C. Carrillo pointed out: “This innovative study in the population of this special Alzheimer’s disease may significantly affect how we prevent Alzheimer’s disease and make individuals make individuals. And the family is avoiding the pain of this fatal disease.

With the development of the test, it not only represents a scientific effort, but also is expected to have nearly 13 million Americans with Alzheimer’s lighthouse by expected by 2050, and there are countless other worldwide. Through the earliest biological changes in the disease, the purpose of researchers not only aims to prevent their symptoms, but also to prevent their appearance.